BioAlliance Pharma Presents Results On Its New Biotherapy Plasmid AMEP™ For Metastatic Melanoma At The American Association For Cancer Research

Main Category: Melanoma / Skin Cancer
Also Included In: Dermatology;  Cancer / Oncology
Article Date: 23 Apr 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

BioAlliance Pharma SA (Euronext Paris - BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results on its new biotherapy, plasmid AMEP™, for metastatic melanoma treatment at the at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009.

Worldwide melanoma incidence is about 140 000 per year with a high frequency especially in Australia, North America and Europe. When treated at early stage, the prognosis of local melanoma is excellent and associated with a prolonged survival. Nevertheless, the five-year survival rate of advanced or metastatic cancers is low, between 5 and 25% according to the stage and localisation of the disease. No treatments or treatment strategies are demonstrated to be consistently effective in these advanced melanoma patients. Recommendations from all medical and scientific cancer and dermatology societies are thus to evaluate new treatments.

Source
BioAlliance Pharma

• Additional
• References
• Citations